IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

Polyherbal Strategies for Inflammation and Oxidative Stress: A Review of Phytochemical Basis, Mechanisms, Standardization and Preclinical Evaluation

Shailesh G. Kathwate[1], Dr. Ravi U. Kurhade[2], Dr. Pratapsinh V. Kachave[3], Mohini S. Survase[4], Vaibhavi V. Mali[5]

[1]M. Pharm Final Year Student, Department of Pharmacology
[2]Principal, Department of Pharmaceutics
[3]Professor, Department of Pharmacology
[4]Assistant Professor, Department of Quality Assurance
[5]Assistant Professor, Department of Pharmachemistry
MDA School of Pharmacy, Kolpa, Latur, Maharashtra

Abstract: *Inflammation and oxidative stress are interdependent biological processes that contribute to edema, pain, mediator amplification and tissue injury. Multi-constituent herbal preparations may be relevant to this interface because different plant materials can contribute antioxidant, membrane-stabilizing, eicosanoid-modulating, cytokine-related and tissue-protective effects. This review summarizes the scientific rationale for a polyherbal formulation comprising Curcuma longa, Boswellia serrata, Emblica officinalis, Glycyrrhiza glabra and Withania somnifera in anti-inflammatory and antioxidant research. The review discusses inflammation biology, oxidative stress biomarkers, phytochemical marker classes, preclinical assay selection, Quality by Design expectations and safety considerations. The reviewed framework supports the view that a polyherbal formulation should be treated as a defined experimental product, requiring botanical authentication, controlled extraction, marker profiling, dose justification, toxicological evaluation and reproducible statistical interpretation. Preclinical outcomes should be interpreted as supportive and hypothesis-generating unless confirmed by mechanism-specific assays and clinical studies.*

Keywords: polyherbal formulation; inflammation; oxidative stress; Curcuma longa; Boswellia serrata; Emblica officinalis; Glycyrrhiza glabra; Withania somnifera; herbal standardization; Quality by Design.

I. INTRODUCTION

Inflammation is a coordinated biological response that protects tissues against infection, traumatic injury, chemical irritation and immune disturbance. It includes recognition of danger signals, vascular permeability, mediator release, leukocyte migration and repair. Acute inflammation is generally protective, but persistent or dysregulated inflammation can lead to chronic tissue damage, angiogenesis, fibrosis and altered immune signaling [1-6].

Oxidative stress is an important amplifier of inflammatory injury. Activated leukocytes and damaged cells generate reactive oxygen and nitrogen species during host defense. When antioxidant defenses are overwhelmed, reactive species damage lipids, proteins and nucleic acids and promote further inflammatory signaling [10-14]. This bidirectional relationship explains why anti-inflammatory research often includes both edema-based endpoints and oxidative biomarkers such as MDA, GSH, SOD and catalase [17-20].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

II. REVIEW METHODOLOGY

This narrative review was prepared from a thesis-based literature framework and selected pharmacology, pharmacognosy, phytochemistry, toxicology and quality-guideline references. Priority was given to publications and guidelines relevant to inflammation mechanisms, oxidative stress biomarkers, carrageenan-induced paw edema, antioxidant assays, herbal drug authentication, polyherbal rationale, safety assessment and Quality by Design. References were organized in Vancouver style, and mechanistic claims were framed conservatively where direct pathway assays were not available.

III. INFLAMMATION-OXIDATIVE STRESS INTERFACE

Inflammatory responses are mediated by cytokines, eicosanoids, nitric oxide, adhesion molecules and reactive species. Prostaglandins generated through cyclooxygenase pathways contribute to pain, edema and fever, whereas leukotrienes generated through lipoxygenase pathways participate in leukocyte recruitment and vascular responses [5,49-52]. NF-kB and MAPK-linked pathways regulate the expression of inflammatory genes, including cytokines, COX-2 and iNOS [7,8]. Oxidative stress is not merely a downstream injury marker. Reactive species can oxidize membranes and proteins, activate redox-sensitive transcription factors and increase inflammatory signaling. Increased MDA suggests lipid peroxidation, while reduced GSH, SOD and catalase suggest impaired endogenous antioxidant defenses [10-14,17-20].



Proposed integrated action: mediator modulation, antioxidant defense, membrane stabilization and tissue protection

Figure 1. Integrated inflammatory and oxidative-stress network targeted by a standardized polyherbal matrix

IV. RATIONALE FOR POLYHERBAL FORMULATION

The polyherbal concept is based on the possibility that different constituent classes may act additively, synergistically or through network-level pharmacology. In inflammation, a single target approach may not fully address vascular changes, leukocyte activation, eicosanoid production, oxidative stress and tissue injury. A standardized polyherbal formulation may therefore be considered when each plant is rationally selected, authenticated and evaluated under controlled conditions [26-28,55].

The selected formulation combines plants that cover major mechanistic areas: Curcuma longa for curcuminoid-associated mediator modulation, Boswellia serrata for boswellic acid and leukotriene-pathway relevance, Emblica officinalis for tannin-rich antioxidant support, Glycyrrhiza glabra for glycyrrhizin-related cytokine and tissue-protective relevance, and Withania somnifera for withanolide-linked stress and inflammatory signaling modulation [29-35].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

Table 1. Phytochemical and mechanistic basis of selected formulation components

Plant	Marker / phytochemical class	Mechanistic relevance	Key caution
Curcuma longa	Curcumin and curcuminoids	NF-kB, COX-2, iNOS and oxidative signaling relevance	Low solubility and variable oral bioavailability
Boswellia serrata	Boswellic acids	5-LOX, leukotriene and anti-edema relevance	Resin quality and marker variability
Emblica officinalis	Emblicanins, tannins and polyphenols	Radical scavenging, lipid peroxidation protection and tissue support	Raw material and extraction variability
Glycyrrhiza glabra	Glycyrrhizin, flavonoids and saponins	Cytokine-related, mucosal and protective support	Excess use may cause mineralocorticoid-like effects
Withania somnifera	Withanolides and steroidal lactones	Stress-response, immunomodulatory and redox support	Marker variation and dose justification required

V. PRECLINICAL EVALUATION MODELS

Preclinical evaluation should combine chemical screening, cellular or ex vivo assays and in vivo evidence. DPPH, ABTS and FRAP assays are useful for screening antioxidant capacity but cannot alone prove biological efficacy because absorption, distribution, metabolism and tissue interaction influence in vivo outcomes [21-23]. Protein denaturation and membrane stabilization assays provide preliminary anti-inflammatory evidence, while carrageenan-induced paw edema offers a reproducible in vivo model of acute inflammation [15,16].

Table 2. Assay selection and interpretation in polyherbal anti-inflammatory research

Endpoint	Assay or marker	Scientific meaning	Interpretation limit
Chemical antioxidant capacity	DPPH, ABTS, FRAP	Radical scavenging and reducing capacity	Does not confirm in vivo efficacy alone
In vitro anti-inflammatory screening	Protein denaturation inhibition	Protection against heat-induced protein damage	Preliminary screening only
Membrane protection	RBC membrane stabilization	Stabilization of biological membranes	Requires in vivo confirmation
Acute inflammation	Carrageenan-induced paw edema	Mediator-driven edema over time	Model-specific result
Oxidative tissue injury	MDA	Lipid peroxidation burden	Requires standardized sample handling
Antioxidant defense	GSH, SOD and catalase	Restoration of endogenous defense	Depends on tissue and assay protocol

VI. QUALITY BY DESIGN AND HERBAL STANDARDIZATION

Herbal pharmacology requires strict standardization because plant identity, geography, season, plant part, drying, particle size, solvent, extraction time, temperature, storage and dose preparation influence activity. Quality by Design helps define the quality target product profile, critical quality attributes, critical material attributes, process parameters and control strategy [36,58-61].

DOI: 10.48175/IJARSCT-37823

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

Table 3. Quality-control expectations for standardized polyherbal research

Quality element	Suggested control	Scientific purpose
Botanical identity	Authentication certificate and voucher specimen	Prevents substitution and adulteration
Plant part and batch data	Source, batch number, date and storage log	Improves traceability
Extraction solvent	Controlled ethanol:water ratio	Improves reproducibility of extract profile
Extract yield	Recorded percentage yield	Supports dose calculation
Marker profiling	HPTLC/HPLC for key markers where possible	Supports batch consistency
Dose uniformity	0.5% CMC suspension with mixing	Ensures reproducible animal dosing
Stability	Amber airtight container at 2-8°C	Reduces degradation
Data integrity	Raw sheets, calibration curves and statistical output	Supports audit and publication quality

VII. SAFETY AND TRANSLATIONAL CONSIDERATIONS

The term herbal should not be equated with automatic safety. Safety evaluation should include acute toxicity observations, behavioral monitoring, mortality, body weight, dose justification and where possible repeated-dose toxicity [24,46]. Glycyrrhiza glabra requires particular caution because excessive licorice exposure may be associated with mineralocorticoid-like effects, hypokalemia and hypertension in susceptible individuals. Boswellia, Curcuma, Emblica and Withania also require dose-specific and extract-specific interpretation.

Clinical claims should not be made solely from in vitro or animal data. Preclinical evidence should be presented as supportive, mechanism-generating and lead-oriented. Translational development requires marker-based standardization, validated pharmacological models, repeated-dose safety, pharmacokinetics, dose optimization and ethically approved human studies [56,57].

VIII. DISCUSSION

The reviewed framework supports a multi-endpoint strategy for evaluating polyherbal anti-inflammatory formulations. A formulation may show chemical antioxidant activity, but the conclusion becomes stronger when antioxidant data align with reduced paw edema, lower MDA, improved GSH/SOD/catalase and histopathological protection. This alignment connects assay-level, functional and tissue-level evidence.

The selected plant combination has a rational phytochemical basis. Curcuma longa and Boswellia serrata contribute mediator-related and eicosanoid-pathway relevance; Emblica officinalis strengthens the antioxidant component; Glycyrrhiza glabra adds tissue-protective and cytokine-related plausibility; and Withania somnifera supports stress-response and immunomodulatory discussion [29-35]. However, such mechanisms remain plausible unless directly confirmed by COX/LOX enzyme assays, cytokine ELISA, iNOS/COX-2 expression analysis or molecular pathway studies.

QbD thinking is essential because a poorly standardized herbal extract may produce results that cannot be reproduced. Authentication, extraction control, marker profiling, storage control and raw data integrity convert the formulation from a vague traditional mixture into a defined research material. This is especially important for publication, regulatory discussion and future clinical translation [36,58-61].

IX. FUTURE SCOPE

Future studies should include HPTLC/HPLC marker profiling of curcumin, boswellic acids, glycyrrhizin, withanolides and amla tannoid markers. Repeated-dose toxicity, cytokine estimation, COX/LOX assays, cellular anti-inflammatory

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

models, pharmacokinetic profiling and formulation optimization using QbD/DoE are recommended. If strong preclinical evidence is reproduced, a carefully designed clinical study may be considered only after regulatory and ethical approval.

X. CONCLUSION

A standardized polyherbal formulation combining Curcuma longa, Boswellia serrata, Emblica officinalis, Glycyrrhiza glabra and Withania somnifera has a biologically plausible role in anti-inflammatory and antioxidant research. Its value lies in multi-target support across mediator modulation, redox balance, membrane stabilization and tissue protection. The formulation should be developed through authentication, controlled extraction, marker standardization, safety testing and reproducible preclinical models. Clinical use cannot be inferred without further mechanistic and human evidence.

REFERENCES

1. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-126.
2. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against chronic diseases. Int J Biochem Cell Biol. 2009;41(1):40-59.
3. Ammon HPT. Boswellic acids and their role in chronic inflammatory diseases. Adv Exp Med Biol. 2016;928:291-327.
4. Ashley NT, Weil ZM, Nelson RJ. Inflammation: mechanisms, costs, and natural variation. Annu Rev Ecol Evol Syst. 2012;43:385-406.
5. Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257-W263.
6. Benzie IFF, Strain JJ. The ferric reducing ability of plasma as a measure of antioxidant power. Anal Biochem. 1996;239(1):70-76.
7. Bhattacharya SK, Muruganandam AV. Adaptogenic activity of Withania somnifera: an experimental study. Pharmacol Biochem Behav. 2003;75(3):547-555.
8. Blois MS. Antioxidant determinations by the use of a stable free radical. Nature. 1958;181:1199-1200.
9. Boots AW, Haenen GRMM, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2-3):325-337.
10. Calixto JB, Otuki MF, Santos ARS. Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B. Planta Med. 2003;69(11):973-983.
11. Chang CC, Yang MH, Wen HM, Chern JC. Estimation of total flavonoid content in propolis by colorimetric methods. J Food Drug Anal. 2002;10(3):178-182.
12. Committee for Control and Supervision of Experiments on Animals. Guidelines for laboratory animal facility. Government of India; 2016.
13. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.
14. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52(4):601-623.
15. Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140(6):935-950.
16. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.
17. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70-77.
18. Evans WC. Trease and Evans Pharmacognosy. 16th ed. Edinburgh: Saunders Elsevier; 2009.
19. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1 beta generation. Clin Exp Immunol. 2007;147(2):227-235.
20. Festing MFW, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002;43(4):244-258.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

21. Firenzuoli F, Gori L. Herbal medicine today: clinical and research issues. Evid Based Complement Alternat Med. 2007;4(Suppl 1):37-40.
22. Gautam R, Jachak SM. Recent developments in anti-inflammatory natural products. Med Res Rev. 2009;29(5):767-820.
23. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 5th ed. Oxford: Oxford University Press; 2015.
24. Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. London: Chapman and Hall; 1998.
25. Heinrich M, Barnes J, Prieto-Garcia J, Gibbons S, Williamson EM. Fundamentals of Pharmacognosy and Phytotherapy. 3rd ed. London: Elsevier; 2018.
26. International Council for Harmonisation. ICH Q10: Pharmaceutical quality system. Geneva: ICH; 2008.
27. International Council for Harmonisation. ICH Q8(R2): Pharmaceutical development. Geneva: ICH; 2009.
28. International Council for Harmonisation. ICH Q9(R1): Quality risk management. Geneva: ICH; 2023.
29. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759.
30. Khandelwal KR. Practical Pharmacognosy: Techniques and Experiments. Pune: Nirali Prakashan; 2008.
31. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines. PLoS Biol. 2010;8(6):e1000412.
32. Koeberle A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today. 2014;19(12):1871-1882.
33. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. Pune: Nirali Prakashan; 2010.
34. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325-1348.
35. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651.
36. Marklund S, Marklund G. Involvement of superoxide anion radical in autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974;47(3):469-474.
37. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428-435.
38. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126-1167.
39. Morris CJ. Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol. 2003;225:115-121.
40. Mukherjee PK. Quality Control and Evaluation of Herbal Drugs. Amsterdam: Elsevier; 2019.
41. Nathan C. Points of control in inflammation. Nature. 2002;420(6917):846-852.
42. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351-358.
43. Organisation for Economic Co-operation and Development. Test No. 423: Acute oral toxicity: acute toxic class method. Paris: OECD Publishing; 2002.
44. Organisation for Economic Co-operation and Development. Test No. 425: Acute oral toxicity: up-and-down procedure. Paris: OECD Publishing; 2008.
45. Parasuraman S, Thing GS, Dhanaraj SA. Polyherbal formulation: concept of Ayurveda. Pharmacogn Rev. 2014;8(16):73-80.
46. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med. 1999;26(9-10):1231-1237.
47. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

48. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220(4597):568-575.
49. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6(12):1191-1197.
50. Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. 2011;73(3):255-261.
51. Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183.
52. Singleton VL, Rossi JA. Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. Am J Enol Vitic. 1965;16:144-158.
53. Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev. 2011;111(10):5821-5865.
54. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44-84.
55. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(3A):2S-8S.
56. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232-235.
57. Variya BC, Bakrania AK, Patel SS. Emblica officinalis: a review for its phytochemistry, ethnomedicinal uses and medicinal potentials. J Complement Integr Med. 2016;13(1):1-11.
58. Wagner H, Bladt S. Plant Drug Analysis: A Thin Layer Chromatography Atlas. 2nd ed. Berlin: Springer; 1996.
59. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401-409.
60. Winter CA, Risley EA, Nuss GW. Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544-547.
61. World Health Organization. WHO Guidelines on Good Herbal Processing Practices for Herbal Medicines. Geneva: World Health Organization; 2018.